{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:53:31Z","timestamp":1785920011739,"version":"3.56.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA158402"],"award-info":[{"award-number":["CA158402"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Flow Cytometry Core Facility of The Cancer Institute of New Jersey","award":["P30CA072720"],"award-info":[{"award-number":["P30CA072720"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.leukres.2015.12.005","type":"journal-article","created":{"date-parts":[[2015,12,19]],"date-time":"2015-12-19T07:03:16Z","timestamp":1450508596000},"page":"85-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Signaling mechanisms of bortezomib in TRAF3-deficient mouse B lymphoma and human multiple myeloma cells"],"prefix":"10.1016","volume":"41","author":[{"given":"Shanique K.E.","family":"Edwards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeming","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Z.","family":"Kreider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhdeep","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carissa R.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2015.12.005_bib0005","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/sj.onc.1210744","article-title":"BCL-2 family regulation by the 20S proteasome inhibitor bortezomib","volume":"27","author":"Fennell","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2015.12.005_bib0010","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1080\/07357900701579570","article-title":"The role of bortezomib in the treatment of lymphoma","volume":"25","author":"Barr","year":"2007","journal-title":"Cancer Invest."},{"key":"10.1016\/j.leukres.2015.12.005_bib0015","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/ijc.21805","article-title":"Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma","volume":"119","author":"Leonard","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.leukres.2015.12.005_bib0020","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/annonc\/mdq009","article-title":"Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies","volume":"21","author":"Reddy","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2015.12.005_bib0025","first-page":"471","article-title":"Advances in the understanding of mechanisms and therapeutic use of bortezomib","volume":"12","author":"Mujtaba","year":"2011","journal-title":"Discov. Med."},{"key":"10.1016\/j.leukres.2015.12.005_bib0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4137\/CMO.S7764","article-title":"Efficacy of bortezomib as first-line treatment for patients with multiple myeloma","volume":"7","author":"Painuly","year":"2013","journal-title":"Clin. Med. Insights Oncol."},{"key":"10.1016\/j.leukres.2015.12.005_bib0035","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MJT.0b013e3181ff7a9e","article-title":"Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy","volume":"19","author":"Driscoll","year":"2012","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.leukres.2015.12.005_bib0040","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1038\/leu.2009.149","article-title":"Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33)","volume":"23","author":"Nagel","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2015.12.005_bib0045","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1182\/blood-2011-06-359166","article-title":"Alteration of BIRC3 and multiple other NF-{kappa}B pathway genes in splenic marginal zone lymphoma","volume":"118","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.12.005_bib0050","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma","volume":"12","author":"Keats","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2015.12.005_bib0055","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","article-title":"Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma","volume":"12","author":"Annunziata","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2015.12.005_bib0060","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1158\/0008-5472.CAN-08-3701","article-title":"Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia","volume":"69","author":"Braggio","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2015.12.005_bib0065","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.immuni.2007.07.012","article-title":"Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs","volume":"27","author":"Xie","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.leukres.2015.12.005_bib0070","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2011.309","article-title":"Specific deletion of TRAF3 in B lymphocytes leads to B lymphoma development in mice","volume":"26","author":"Moore","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2015.12.005_bib0075","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.immuni.2008.01.009","article-title":"TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor","volume":"28","author":"Gardam","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.leukres.2015.12.005_bib0080","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/ni.1678","article-title":"Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling","volume":"9","author":"Vallabhapurapu","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.leukres.2015.12.005_bib0085","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/ni.1676","article-title":"Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK","volume":"9","author":"Zarnegar","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.leukres.2015.12.005_bib0090","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1186\/1471-2407-13-481","article-title":"N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma","volume":"13","author":"Edwards","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.leukres.2015.12.005_bib0095","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.leukres.2013.12.016","article-title":"Expression and function of a novel isoform of Sox5 in malignant B cells","volume":"38","author":"Edwards","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2015.12.005_bib0100","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-014-0056-6","article-title":"Mutated in colorectal cancer (MCC) is a novel oncogene in B lymphocytes","volume":"7","author":"Edwards","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2015.12.005_bib0105","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/pro.546","article-title":"Highly efficient purification of protein complexes from mammalian cells using a novel streptavidin-binding peptide and hexahistidine tandem tag system: application to Bruton's tyrosine kinase","volume":"20","author":"Li","year":"2010","journal-title":"Protein Sci."},{"key":"10.1016\/j.leukres.2015.12.005_bib0110","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1128\/JVI.01770-08","article-title":"MyD88 intrinsically regulates CD4 T-cell responses","volume":"83","author":"Zhou","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.leukres.2015.12.005_bib0115","first-page":"1136","article-title":"The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents","volume":"9","author":"Ma","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2015.12.005_bib0120","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","article-title":"Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells","volume":"114","author":"Hideshima","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.12.005_bib0125","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1158\/1541-7786.MCR-08-0108","article-title":"Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells","volume":"6","author":"Markovina","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.leukres.2015.12.005_bib0130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4161\/cbt.4.1.1379","article-title":"The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells","volume":"4","author":"Matta","year":"2005","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.leukres.2015.12.005_bib0135","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/sj.leu.2404278","article-title":"Proteasome inhibitor bortezomib for the treatment of multiple myeloma","volume":"20","author":"Cavo","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2015.12.005_bib0140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.critrevonc.2014.05.003","article-title":"Linking the activity of bortezomib in multiple myeloma and autoimmune diseases","volume":"92","author":"Skrott","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.leukres.2015.12.005_bib0145","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/j.seminhematol.2012.04.010","article-title":"Bortezomib combination therapy in multiple myeloma","volume":"49","author":"Kapoor","year":"2012","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.leukres.2015.12.005_bib0150","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1158\/1078-0432.CCR-03-0561","article-title":"Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors","volume":"10","author":"Pei","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2015.12.005_bib0155","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1158\/0008-5472.CAN-06-4322","article-title":"Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma","volume":"67","author":"Gomez-Bougie","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2015.12.005_bib0160","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/sj.onc.1210679","article-title":"A pivotal role for Mcl-1 in Bortezomib-induced apoptosis","volume":"27","author":"Podar","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2015.12.005_bib0165","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1756-9966-29-8","article-title":"Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types","volume":"29","author":"Ling","year":"2010","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2015.12.005_bib0170","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood.V95.3.1039.003k02_1039_1046","article-title":"CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines","volume":"95","author":"Teoh","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.12.005_bib0175","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1038\/leu.2014.102","article-title":"p53 haploinsufficiency and functional abnormalities in multiple myeloma","volume":"28","author":"Teoh","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2015.12.005_bib0180","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1158\/1535-7163.MCT-13-0123","article-title":"Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro","volume":"12","author":"Hu","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.leukres.2015.12.005_bib0185","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1158\/1535-7163.MCT-10-0471","article-title":"RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses","volume":"9","author":"Saha","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.leukres.2015.12.005_bib0190","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","article-title":"The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status","volume":"107","author":"Perez-Galan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.12.005_bib0195","doi-asserted-by":"crossref","first-page":"19488","DOI":"10.1073\/pnas.0708380104","article-title":"Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition","volume":"104","author":"Nikiforov","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.leukres.2015.12.005_bib0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cgt.2012.84","article-title":"A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia","volume":"20","author":"Zhang","year":"2013","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.leukres.2015.12.005_bib0205","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.bbamcr.2008.01.008","article-title":"Induction of p21 by p65 in p53 null cells treated with Doxorubicin","volume":"1783","author":"Ma","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.leukres.2015.12.005_bib0210","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1158\/1535-7163.MCT-09-1159","article-title":"p53-independent induction of G1 arrest and p21WAF1\/CIP1 expression by ascofuranone, an isoprenoid antibiotic, through downregulation of c-Myc","volume":"9","author":"Jeong","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.leukres.2015.12.005_bib0215","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2006-07-034173","article-title":"The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak","volume":"109","author":"Perez-Galan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.12.005_bib0220","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1158\/1535-7163.MCT-05-0437","article-title":"Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells","volume":"5","author":"Canfield","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.leukres.2015.12.005_bib0225","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1158\/1541-7786.MCR-12-0133","article-title":"Roles of estrogen receptor and p21(Waf1) in bortezomib-induced growth inhibition in human breast cancer cells","volume":"10","author":"Maynadier","year":"2012","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.leukres.2015.12.005_bib0230","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cbin.10139","article-title":"Bortezomib induces apoptosis of endometrial cancer cells through microRNA-17-5p by targeting p21","volume":"37","author":"Shen","year":"2013","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.leukres.2015.12.005_bib0235","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/464972a","article-title":"Big science: The cancer genome challenge","volume":"464","author":"Ledford","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2015.12.005_bib0240","doi-asserted-by":"crossref","unstructured":"Consortium TICG: International network of cancer genome projects, Nature (2010); 464:993\u2013998.","DOI":"10.1038\/nature08987"},{"key":"10.1016\/j.leukres.2015.12.005_bib0245","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.cell.2010.05.034","article-title":"Whole-genome sequencing breaks the cost barrier","volume":"141","author":"Bonetta","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2015.12.005_bib0250","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cell.2010.03.032","article-title":"Genetic heterogeneity in human disease","volume":"141","author":"McClellan","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2015.12.005_bib0255","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/PPO.0000000000000014","article-title":"Genetics of diffuse large B-cell lymphoma: paving a path to personalized medicine","volume":"20","author":"King","year":"2014","journal-title":"Cancer J."},{"key":"10.1016\/j.leukres.2015.12.005_bib0260","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.2010.34.0760","article-title":"Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma","volume":"29","author":"Mitsiades","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2015.12.005_bib0265","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1158\/1078-0432.CCR-12-0779","article-title":"Dual inhibition of canonical and noncanonical NF-kappaB pathways demonstrates significant antitumor activities in multiple myeloma","volume":"18","author":"Fabre","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2015.12.005_bib0270","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1158\/0008-5472.CAN-04-0268","article-title":"Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice","volume":"65","author":"Park","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2015.12.005_bib0275","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.bcmd.2010.08.002","article-title":"The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma","volume":"45","author":"Smith","year":"2010","journal-title":"Blood Cells Mol. Dis."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615305622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615305622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T00:31:13Z","timestamp":1599957073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212615305622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":55,"alternative-id":["S0145212615305622"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2015.12.005","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Signaling mechanisms of bortezomib in TRAF3-deficient mouse B lymphoma and human multiple myeloma cells","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2015.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}